-
Something wrong with this record ?
Hypothermic Ex Situ Perfusion of Human Limbs With Acellular Solution for 24 Hours
V. Haug, B. Kollar, S. Tasigiorgos, Y. Endo, M. Kauke, AF. Safi, A. Veeramani, O. Abdulrazzak, B. Bausk, D. Walt, B. Pomahac,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Allografts MeSH
- Cytokines analysis MeSH
- Adult MeSH
- Extremities blood supply surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Cold Temperature MeSH
- Perfusion methods MeSH
- Replantation methods MeSH
- Organ Preservation Solutions MeSH
- Warm Ischemia MeSH
- Organ Preservation methods MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Machine perfusion (MP) has evolved as a promising approach for the ex situ preservation in organ transplantation. However, the literature on the use of MP in human vascularized composite allografts is scarce. The aim of this study was to evaluate the effects of hypothermic MP with an acellular perfusate in human upper extremities and compare with the current gold standard of static cold storage (SCS). METHODS: Six upper extremities were assigned to either MP (n = 3) or SCS (n = 3) conditions for 24 h. MP-extremities were perfused with oxygenated Steen solution at a constant pressure of 30 mm Hg and 10°C. RESULTS: Median total ischemia time was 213 min (range, 127-222 min). Myoglobin, creatine-kinase (CK) showed increased levels at the start of MP (medians: myoglobin: 4377 ng/mL, CK: 1442 U/L), peaking 6 h after perfusate exchange (medians: myoglobin: 9206 ng/mL, CK: 3995 U/L) at timepoint 24. Lactate levels decreased from a median of 6.9-2.8 mmol/L over time. Expression of hypoxia-inducible factor 1-alpha peaked in the SCS-group after 8 h, followed by a decrease. Increased hypoxia-inducible factor 1-alpha expression in the MP group was delayed until 20 h. Perfusion pressure, temperature, and circuit flow were maintained at median of 30.88 mm Hg, 9.77°C, and 31.13 mL/min, respectively. Weight increased 1.4% in the SCS group and 4.3% in the MP group over 24 h. CONCLUSIONS: Hypothermic ex situ perfusion with an oxygenated acellular Steen solution may extend the allowable extracorporeal preservation time by a factor of 4-6 compared to SCS and holds promise to be beneficial for vascularized composite allograft recipients and victims of traumatic major limb amputation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21001325
- 003
- CZ-PrNML
- 005
- 20210119110838.0
- 007
- ta
- 008
- 210119s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/TP.0000000000003221 $2 doi
- 035 __
- $a (PubMed)32168040
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Haug, Valentin $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Department of Hand, Plastic and Reconstructive Surgery, Microsurgery, Burn Trauma Center, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany.
- 245 10
- $a Hypothermic Ex Situ Perfusion of Human Limbs With Acellular Solution for 24 Hours / $c V. Haug, B. Kollar, S. Tasigiorgos, Y. Endo, M. Kauke, AF. Safi, A. Veeramani, O. Abdulrazzak, B. Bausk, D. Walt, B. Pomahac,
- 520 9_
- $a BACKGROUND: Machine perfusion (MP) has evolved as a promising approach for the ex situ preservation in organ transplantation. However, the literature on the use of MP in human vascularized composite allografts is scarce. The aim of this study was to evaluate the effects of hypothermic MP with an acellular perfusate in human upper extremities and compare with the current gold standard of static cold storage (SCS). METHODS: Six upper extremities were assigned to either MP (n = 3) or SCS (n = 3) conditions for 24 h. MP-extremities were perfused with oxygenated Steen solution at a constant pressure of 30 mm Hg and 10°C. RESULTS: Median total ischemia time was 213 min (range, 127-222 min). Myoglobin, creatine-kinase (CK) showed increased levels at the start of MP (medians: myoglobin: 4377 ng/mL, CK: 1442 U/L), peaking 6 h after perfusate exchange (medians: myoglobin: 9206 ng/mL, CK: 3995 U/L) at timepoint 24. Lactate levels decreased from a median of 6.9-2.8 mmol/L over time. Expression of hypoxia-inducible factor 1-alpha peaked in the SCS-group after 8 h, followed by a decrease. Increased hypoxia-inducible factor 1-alpha expression in the MP group was delayed until 20 h. Perfusion pressure, temperature, and circuit flow were maintained at median of 30.88 mm Hg, 9.77°C, and 31.13 mL/min, respectively. Weight increased 1.4% in the SCS group and 4.3% in the MP group over 24 h. CONCLUSIONS: Hypothermic ex situ perfusion with an oxygenated acellular Steen solution may extend the allowable extracorporeal preservation time by a factor of 4-6 compared to SCS and holds promise to be beneficial for vascularized composite allograft recipients and victims of traumatic major limb amputation.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a alografty $7 D064591
- 650 _2
- $a nízká teplota $7 D003080
- 650 _2
- $a cytokiny $x analýza $7 D016207
- 650 _2
- $a končetiny $x krevní zásobení $x chirurgie $7 D005121
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a uchovávání orgánů $x metody $7 D009926
- 650 _2
- $a roztoky pro uchovávání orgánů $7 D019188
- 650 _2
- $a perfuze $x metody $7 D010477
- 650 _2
- $a replantace $x metody $7 D012092
- 650 _2
- $a teplá ischemie $7 D052096
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kollar, Branislav $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Tasigiorgos, Sotirios $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Endo, Yori $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Kauke, Martin $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Safi, Ali-Farid $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Veeramani, Anamika $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Abdulrazzak, Obada $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
- 700 1_
- $a Bausk, Bruce $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Wyss Institute for Bioinspired Engineering at Harvard University, Boston, MA.
- 700 1_
- $a Walt, David $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Wyss Institute for Bioinspired Engineering at Harvard University, Boston, MA.
- 700 1_
- $a Pomahač, Bohdan, $u Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. $d 1971- $7 xx0117402
- 773 0_
- $w MED00010695 $t Transplantation $x 1534-6080 $g Roč. 104, č. 9 (2020), s. e260-e270
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32168040 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210119 $b ABA008
- 991 __
- $a 20210119110835 $b ABA008
- 999 __
- $a ok $b bmc $g 1611146 $s 1121608
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 104 $c 9 $d e260-e270 $e - $i 1534-6080 $m Transplantation $n Transplantation $x MED00010695
- LZP __
- $a Pubmed-20210119